Meeting
2022 ASCO Annual Meeting
Phase II multicentric Italian trial on repositioning of the antipsychotic drug chlorpromazine and its combination with temozolomide in patients with MGMT unmethylated glioblastoma: The RACTAC trial.
Authors
Giuseppe Lombardi
Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
Giuseppe Lombardi , Marco Giorgio Paggi , Silvia Matteoni , Veronica Villani , Dario Benincasa , Claudia Abbruzzese , Giulia Cerretti , Marta Padovan , Mario Caccese , Antonio Silvani , Andrea Pace
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT04224441
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2073)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2073
Abstract #
TPS2073
Poster Bd #
411a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.
First Author: Paul James Mulholland
Poster
2023 ASCO Annual Meeting
Final analysis of 2-THE-TOP: A phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma.
First Author: David D. Tran
Poster
2023 ASCO Annual Meeting
Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).
First Author: Daniela Annenelie Bota
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen